The drug discovery outsourcing market is expected to expand its roots at a steady CAGR of 7.2% during the forecast period. The market is likely to hold a revenue of US$ 3.75 billion in 2023, while it is anticipated to cross a value of US$ 7.52 billion by 2033.
The research report on the drug discovery outsourcing market states that the pharmaceutical industry is expanding thoroughly with new extensions and high-end research programs. The higher penetration of smart technology in the drug discovery and development process is likely to transform the market condition. Furthermore, AI drug discovery outsourcing is much cheaper, easy, and integrated. Thus, pharmaceutical brands adopt these newly designed methods to increase reliability and promote cruelty-free discovery. Alongside this, the growing outsourcing trend in Asian economies like India and China is likely to strengthen the pharmaceutical ties between the West and East. The wave of novel drug discovery in India, with brands building their projects around the Indian drug discovery outsourcing space, is anticipated to flourish the market growth. Moreover, the government projects and the bilateral relationship are also anticipated to increase drug production. This pushes pharma companies to look for biomedical advancements.
The market dynamics have been affected by the pandemic, the geriatric population, and new diseases spreading out of nations. Thus, the consumption of advanced drugs, drug mixtures (synergistic drugs), and other anti-infection drugs are likely to put pressure on the brands. This leads pharmaceutical companies to reach out to distant markets to reduce the cost of production and research of drug discovery and development.
The use of stimulating organs coupled with organs-on-chips for disease modeling and drug development is likely to change the market dynamic. From hit confirmation to lead optimization and high-speed screening services, the smart tech has reformed each component of the drug discovery systems. An estimate states that 80% of the research for different pharmaceutical elements can be outsourced. Thus, the drug discovery outsourcing market is likely to garner during the forecast period.
| Attributes | Details |
|---|---|
| Drug Discovery Outsourcing Market CAGR (2023 to 2033) | 7.2% |
| Drug Discovery Outsourcing Market Size (2023) | US$ 3.75 billion |
| Drug Discovery Outsourcing Market Size (2033) | US$ 7.52 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to FMI analysis, the drug discovery outsourcing market was valued at US$ 3.50 billion in 2022 and is likely to be worth US$ 7.52 billion by 2033.
AI-enabled drug discovery methods, along with the expanding research and development programs, are garnering market growth. The increased penetration of innovation, reduced costs, and pharmaceutical companies collaborating for the research part fuel the market growth.
The application of AI in protein modeling, digital organ simulation, and organ-on-a-chip is also easing the drug discovery process. Developing nations like India and China are becoming the center stage for the pharmaceutical revolution with mass drug production and extended research and development programs. The AI-driven drug discovery is anticipated to increase the capital investment in distant lands to expand their production and research workforce. Alongside this, the new AI drug discovery outsourcing services are likely to enhance target identification, patient stratification, and biomarker development.
As COVID-19 pandemic garnered the pharmaceutical industry, new viruses and their penetration in developed nations are also increasing drug consumption. Even developing nations enhancing public health conditions are adopting advanced drug discovery measures. Similarly, they are indulged in collaborating with cheaper third-party research and development vendors.
Principal Consultant
Key restraints for the drug discovery outsourcing market are governmental restrictions, higher outsourcing costs, and tariffs restraining market growth. The rapidly expanding space for alternative medicine and limited medical budgets are limiting the growth of the market.
Increased Demand for Research and Development along with Expanding Bilateral Ties are making North America the Top Growing Region
North America region leads in terms of the market share in the drug discovery outsourcing market with a market share CAGR of 35.5%. The growth is attributed to lower research costs, higher innovative experiments, and increasing demand for generic and disease-specific drugs. Furthermore, companies collaborating with third-party drug discovery service vendors are likely to impact the market positively. The rising competition is fueled by factors such as higher efficiency, quality, and innovation is garnering regional growth.
Integration of Smart Technologies coupled with Heavy Demand for Generic Medicine is Fuelling the Demand for Drug Discovery Outsourcing
Asia Pacific region leads the market in terms of CAGR between 2023 and 2033. Japan drug discovery outsourcing markets in the Asia Pacific region. Apart from the higher population and higher investment, the Japanese market comes in the pharmaceutical market due to smart technology integration. The AI-enabled drug discovery method is transforming the industry with fast, reliable, inexpensive, and cruelty-free drug discovery.
Concepts like Digital Organ Simulation and Organ-on-a-chip are collectively flourishing the Regional Growth
The United Kingdom is another significant market for drug discovery outsourcing systems. The increase in virus mutations and deadly chronic diseases is pushing the demand for drug discovery outsourcing. Better prediction in human drug discovery also impacts the various treatment garnering market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Category | By Workflow |
|---|---|
| Leading Segment | Lead Identification & Candidate Optimization |
| Market Share % (2022) | 32.3% |
| Category | By Therapeutic Area |
|---|---|
| Leading Segment | Respiratory Systems |
| Market Share % (2022) | 14% |
Based on the workflow, lead identification & candidate optimization held the leading share of 32.3% in 2022. The growth is attributed to better workflow management. Also, increased activity around the non-bonded interaction and reduced side effects are making this segment more popular in the category. It is expected to improve potency and dynamics as well.
Based on the therapeutic area, the respiratory systems segment held a share of 14.0% in 2022. The higher amount of chronic diseases impacting the respiratory organs and developing various chronic and non-chronic diseases are thriving segmental growth. The therapeutic areas involve oncology, ophthalmology, hematology, cardiovascular, endocrine, and others. The diseases like bronchitis, tuberculosis, COPD, and asthma fuel the segment growth.
The key players focus on adopting advanced AI-enabled drug discovery outsourcing services. The end users choose the vendors that not only provide better pricing but also efficient quality and timing. Companies also merge, collaborate, and acquire in order to expand their sales and distributional channels.
Market Developments
The drug discovery outsourcing market is valued at US$ 3.75 billion in 2023.
Albany Molecular Research Inc., EVOTEC and Laboratory Corporation of America Holdings are key players.
The drug discovery outsourcing market will reach US$ 7.52 billion by 2033.
AI-driven drug discovery, expanding R&D, innovation adoption, cost reduction, and pharma collaboration propel the market.
Lead Identification & Candidate Optimization segment to remain preferred in the market through 2033.
1. Executive Summary | Drug Discovery Outsourcing Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Workflow 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Workflow, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Workflow, 2023 to 2033 5.3.1. Target Identification & Screening 5.3.2. Target Validation & Functional Informatics 5.3.3. Lead Identification & Candidate Optimization 5.3.4. Preclinical Development 5.3.5. Other Associated Workflow 5.4. Y-o-Y Growth Trend Analysis By Workflow, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Workflow, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutics Area 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Therapeutics Area, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutics Area, 2023 to 2033 6.3.1. Respiratory system 6.3.2. Pain and Anaesthesia 6.3.3. Oncology 6.3.4. Ophthalmology 6.3.5. Haematology 6.3.6. Cardiovascular 6.3.7. Endocrine 6.3.8. Gastrointestinal 6.3.9. Immunomodulation 6.3.10. Dermatology 6.3.11. Central Nervous System 6.3.12. Genitourinary System 6.4. Y-o-Y Growth Trend Analysis By Therapeutics Area, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Therapeutics Area, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 7.3.1. Small Molecules 7.3.2. Large Molecules 7.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 8.3.1. Pharmaceutical and Biotechnology companies 8.3.2. Academic Institutes 8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Workflow 10.2.3. By Therapeutics Area 10.2.4. By Drug Type 10.2.5. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Workflow 10.3.3. By Therapeutics Area 10.3.4. By Drug Type 10.3.5. By End User 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Workflow 11.2.3. By Therapeutics Area 11.2.4. By Drug Type 11.2.5. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Workflow 11.3.3. By Therapeutics Area 11.3.4. By Drug Type 11.3.5. By End User 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Workflow 12.2.3. By Therapeutics Area 12.2.4. By Drug Type 12.2.5. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Workflow 12.3.3. By Therapeutics Area 12.3.4. By Drug Type 12.3.5. By End User 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Workflow 13.2.3. By Therapeutics Area 13.2.4. By Drug Type 13.2.5. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Workflow 13.3.3. By Therapeutics Area 13.3.4. By Drug Type 13.3.5. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Workflow 14.2.3. By Therapeutics Area 14.2.4. By Drug Type 14.2.5. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Workflow 14.3.3. By Therapeutics Area 14.3.4. By Drug Type 14.3.5. By End User 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Workflow 15.2.3. By Therapeutics Area 15.2.4. By Drug Type 15.2.5. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Workflow 15.3.3. By Therapeutics Area 15.3.4. By Drug Type 15.3.5. By End User 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Workflow 16.2.3. By Therapeutics Area 16.2.4. By Drug Type 16.2.5. By End User 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Workflow 16.3.3. By Therapeutics Area 16.3.4. By Drug Type 16.3.5. By End User 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Workflow 17.1.2.2. By Therapeutics Area 17.1.2.3. By Drug Type 17.1.2.4. By End User 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Workflow 17.2.2.2. By Therapeutics Area 17.2.2.3. By Drug Type 17.2.2.4. By End User 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Workflow 17.3.2.2. By Therapeutics Area 17.3.2.3. By Drug Type 17.3.2.4. By End User 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Workflow 17.4.2.2. By Therapeutics Area 17.4.2.3. By Drug Type 17.4.2.4. By End User 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Workflow 17.5.2.2. By Therapeutics Area 17.5.2.3. By Drug Type 17.5.2.4. By End User 17.6. United kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Workflow 17.6.2.2. By Therapeutics Area 17.6.2.3. By Drug Type 17.6.2.4. By End User 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Workflow 17.7.2.2. By Therapeutics Area 17.7.2.3. By Drug Type 17.7.2.4. By End User 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Workflow 17.8.2.2. By Therapeutics Area 17.8.2.3. By Drug Type 17.8.2.4. By End User 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Workflow 17.9.2.2. By Therapeutics Area 17.9.2.3. By Drug Type 17.9.2.4. By End User 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Workflow 17.10.2.2. By Therapeutics Area 17.10.2.3. By Drug Type 17.10.2.4. By End User 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Workflow 17.11.2.2. By Therapeutics Area 17.11.2.3. By Drug Type 17.11.2.4. By End User 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Workflow 17.12.2.2. By Therapeutics Area 17.12.2.3. By Drug Type 17.12.2.4. By End User 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Workflow 17.13.2.2. By Therapeutics Area 17.13.2.3. By Drug Type 17.13.2.4. By End User 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Workflow 17.14.2.2. By Therapeutics Area 17.14.2.3. By Drug Type 17.14.2.4. By End User 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Workflow 17.15.2.2. By Therapeutics Area 17.15.2.3. By Drug Type 17.15.2.4. By End User 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Workflow 17.16.2.2. By Therapeutics Area 17.16.2.3. By Drug Type 17.16.2.4. By End User 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Workflow 17.17.2.2. By Therapeutics Area 17.17.2.3. By Drug Type 17.17.2.4. By End User 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Workflow 17.18.2.2. By Therapeutics Area 17.18.2.3. By Drug Type 17.18.2.4. By End User 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Workflow 17.19.2.2. By Therapeutics Area 17.19.2.3. By Drug Type 17.19.2.4. By End User 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Workflow 17.20.2.2. By Therapeutics Area 17.20.2.3. By Drug Type 17.20.2.4. By End User 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Workflow 17.21.2.2. By Therapeutics Area 17.21.2.3. By Drug Type 17.21.2.4. By End User 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Workflow 18.3.3. By Therapeutics Area 18.3.4. By Drug Type 18.3.5. By End User 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Albany Molecular Research Inc. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. EVOTEC 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Laboratory Corporation of America Holdings 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. GenScript 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Pharmaceutical Product Development, LLC 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Merck & Co., Inc. 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Thermo Fisher Scientific Inc. 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Dalton Pharma Services 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Dr. Reddy Laboratories Ltd. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Pharmaron Beijing Co., Ltd. 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.11. TCG Lifesciences Pvt Ltd. 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 19.1.12. Domainex Ltd. 19.1.12.1. Overview 19.1.12.2. Product Portfolio 19.1.12.3. Profitability by Market Segments 19.1.12.4. Sales Footprint 19.1.12.5. Strategy Overview 19.1.12.5.1. Marketing Strategy 19.1.13. Eurofins SE 19.1.13.1. Overview 19.1.13.2. Product Portfolio 19.1.13.3. Profitability by Market Segments 19.1.13.4. Sales Footprint 19.1.13.5. Strategy Overview 19.1.13.5.1. Marketing Strategy 19.1.14. Syngene International Limited 19.1.14.1. Overview 19.1.14.2. Product Portfolio 19.1.14.3. Profitability by Market Segments 19.1.14.4. Sales Footprint 19.1.14.5. Strategy Overview 19.1.14.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Drug Discovery Outsourcing Market
